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ABSTRACT 
 
Background and Aim: Although des-γ-carboxy prothrombin (DCP) is known to be an 
useful serum biomarker for the diagnosis of hepatocellular carcinoma (HCC) and could 
serve as a preoperative indicator in assessing HCC progression, the clinical usefulness of 
DCP in Chinese patients with HCC predominantly caused by hepatitis B virus (HBV) 
infection has yet been fully confirmed. This large-scale, multi-center case-controlled study 
aimed to ascertain the clinical utility of DCP in HCC diagnosis as well as the relation 
between DCP expression and the prognosis for Chinese HCC patients. 
 
Methods: Subjects were 1,153 individuals from three major hospitals in China, including 
550 cases in HCC group, 164 cases in Malignant disease group, 181 cases in Benign 
disease group, 85 cases in Chronic liver disease group, and 173 cases in Normal group. 
Serum levels of DCP and AFP were measured and clinicopathological features were 
determined for all subjects. The variables of tumor number, tumor differentiation, 
microvascular invasion, satellite node, and TNM stage from 112 HCC cases were also 
collected. 
 
Results: The levels of DCP and AFP were significantly higher in HCC group (550 patients, 
74.18% with HBV infection) than that in other four groups (P < 0.001). Receiver operating 
curves (ROC) indicated the optimal cut-off value was 86 mAU/mL for DCP with a 
sensitivity of 71.50% and specificity of 86.30%, and 21 ng/mL for AFP with a sensitivity of 
68.00% and specificity of 93.20%. The area under ROC curve was 0.846 for DCP, 0.832 
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for AFP, and 0.890 for the combination of DCP and AFP. The combination of DCP and 
AFP resulted in a higher Youden index and a sensitivity of approximately 90%, even for 
small tumors. Furthermore, the high level of serum DCP was significantly associated with 
larger tumor size, poorly differentiated tumor, presence of microvascular invasion, more 
advanced TNM stage, or presence of tumor recurrence. The 3-year survival for HCC 
patients with high serum DCP level was significantly poorer than those with low serum 
DCP levels (3-year survival rate: 54.53% vs. 81.82%, P = 0.007). 
 
Conclusions: The simultaneous measurement of DCP and AFP could achieve a better 
sensitivity in diagnosing Chinese HCC patients, even for small tumors. Serum DCP could 
serve as a preoperative indicator in assessing progression for Chinese patients with HCC. 
To improve the ability of serum biomarkers in HCC diagnosis and prognosis, the combined 
testing of DCP and AFP is suggested to be widely used in China. 
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1. Introduction 
 
Hepatocellular carcinoma (HCC) is the fifth most prevalent malignancy and the second 
leading cause of cancer deaths worldwide, with an estimated global incidence of 782,000 
new cases and nearly 746,000 deaths in 2012 (1, 2). HCC is prevalent in Eastern and 
South-Eastern Asia, with an incidence of 31.9/100,000 and 22.2/100,000, where the major 
risk factor is hepatitis B virus (HBV) (1, 2). Of particular note is the fact that China alone 
accounts for 50% of HCC cases worldwide, with a total prevalence of 26-32/10,000 and a 
prevalence as high as 70-80/10,000 in some areas (3, 4).  
HCC is one of the most difficult to treat malignances. Surgical resection and liver 
transplantation are thought to be curative therapies for HCC. However, fewer than 30% of 
all patients are eligible candidates due to poor liver function, advanced disease at the time 
of diagnosis, limited donor livers, or a combination of those factors (5, 6). For 
intermediate-to-late stage HCC, locoregional therapies including transcatheter arterial 
chemoembolization (TACE) and radiofrequency ablation (RFA) are available but suited to 
a limited portion of patients with liver tumors qualifying for palliative care (7). To achieve 
the most from available therapies, the most promising strategy is to diagnose and treat 
high-risk populations early on since HCC might be detected in an early curable stage and 
result in long-term survival - evidence showed that the normal overall 5-year survival rate 
for patients with HCC was 40%, but with a liver resection to treat early HCC, the 5-year 
survival rate could rise to 60-70% (8, 9).  
In order to determine how HCC is detected in its early stages worldwide, we made 
a systematically literature reviewed in 2012 consisting of 3,008 papers included in the 
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PubMed database from 2001 to 2011 (10, 11). The characteristic 17 guidelines for HCC 
management worldwide have also been analyzed, including 5 guidelines from the America, 
7 from Asia, and 5 from Europe (Table 1) (6, 12-27). Results of literature analysis showed 
that surveillance and early diagnosis for high-risk patients with HBV- or HCV-related 
chronic liver diseases could improve the rate of early HCC detection and the rate of 
curative treatment, which had been confirmed by several cohort studies and recommended 
by the guidelines for HCC (28-30). For the diagnostic tools, worldwide, while imaging 
diagnostic tools are widely used in Western countries, the serum biomarkers are still 
regarded as useful tools for HCC early diagnosis in Asian countries (Figure 1) (10) (31, 32). 
In China, the most prevalent early diagnostic tools have been serum 
alpha-fetoprotein (AFP) and ultrasonography until now (Table 2) (10, 31, 33-36). AFP is 
the serum biomarker most widely used in China since 1970s, and its clinical usefulness was 
confirmed by a randomized controlled trial of 18,816 Chinese patients in 2004 (9). 
However, AFP levels are normal in up to 40% of patients with HCC, particularly during the 
early stage of the disease (low sensitivity) (37, 38), and elevated AFP levels are seen in 
patients with cirrhosis or exacerbation of chronic hepatitis (low specificity) (39, 40). 
Furthermore, some studies have indicated that AFP has substantially limited diagnostic 
accuracy in detecting small HCC (41). Thus, other reliable serum biomarkers need to be 
identified to complement AFP in order to improve clinical outcomes for patients. 
Worldwide, a number of studies have looked at des-gamma-carboxy prothrombin 
(DCP), also known as prothrombin induced by vitamin K absence-II (PIVKA-II). 
Numerous studies have found that the combined testing of DCP and AFP has a sensitivity 
of 47.5-94.0% and a specificity of 53.3-98.5% in HCC early diagnosis, and these figures  
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Table 1. Characteristics of current 17 guidelines for HCC around the world 
Areas Guidelines/Approach Content Evaluation measures Draft by 
America     
2005 AASLD Guideline/LA (6) D&T + S evidence categories and 
recommendation grades; 
dissemination evaluation 
American Association for the Study of 
Liver Disease 
2007 ACS Guideline/EC (12) D&T — American College of Surgeons 
2009 NCCN Guideline/EC (13) D&T + E + S consensus categories National Comprehensive Cancer 
Network 
2010 WGO Guideline/EC (14) D&T + E + P 
+ S 
resource-based recommendations World Gastroenterology Organization
2010 NCI Guideline/EC (15) D&T + E — United States National Cancer 
Institute 
     
Asia     
2004 Korean Guideline/LA (16) D&T evidence categories and 
recommendation grades 
Korean Liver Cancer Study Group 
and National Cancer Center 
2005 J-HCC Guideline/LA†(17) D&T + P + S evidence categories and 
recommendation grades; 
dissemination evaluation draft; 
evaluation prior 
to publication 
Japanese Ministry of Health, Labor, 
and Welfare 
2006 SGA Guideline/LA (18) D&T + E + P evidence categories and 
recommendation grades 
Saudi Gastroenterology Association 
2007 JSH Guideline/EC (19) D&T + S question and answer analyser 
system 
Japan Society of Hepatology 
2009 AOS Guideline/EC (20) D&T + P + S evidence categories and 
recommendation grades; 
resource-based recommendations 
Asian Oncology Summit 2009 
2009 Chinese Guideline/EC (21) D&T — Chinese Society of Liver Cancer, 
Chinese Society of Clinical Oncology,
Chinese Society of Hepatology Liver 
Cancer Study Group 
2010 APASL Guideline/EC† 
(22) 
D&T + E + P 
+ S 
evidence categories and consensus 
grade 
Asian-Pacific Association for the 
Study of the Liver 
     
Europe     
2001 EASL Guideline/EC (23) D&T + E + P 
+ S 
— European Association for the Study of 
the Liver 
2003 BSG Guideline/LA (24) D&T + E + S evidence categories and 
recommendation grades 
British Society of Gastroenterology 
2004 BASL Guideline/EC (25) D&T + E + P 
+ S 
— Belgian Association for the Study of 
the Liver 
2008 ESMO Guideline/EC (26) D&T + E + P 
+ S + F 
dissemination evaluation European Society for Medical 
Oncology 
2009 GOIM Guideline/EC (27) D&T + E — Italian Southern Oncological Group 
LA, literature analysis; EC, expert consensus; † Experts consist of radiologists, statisticians, and other experts besides hepatologists; the 
others were drafted by hepatologists; E, epidemiology; P, prevention; S, surveillance; D&T, diagnosis and treatment; E, epidemiology; P, 
prevention; S, surveillance; F, follow-up. 
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Figure 1. The diagnostic algorithm in current 17 guidelines for HCC management 
worldwide. 
 
Worldwide, while imaging diagnostic tools are widely used in Western countries, the serum 
biomarkers are still regarded as useful tools for HCC early diagnosis in Asian countries. In 
Japan, US and AFP/DCP/AFP-L3 are recommended to be performed every 3-4 months for 
the highest-risk group (HBV- or HCV-related liver cirrhosis patients) and every 6-month 
for the high-risk group (patients with HBV- or HCV-related chronic liver disease or liver 
cirrhosis due to other causes). US, ultrasonography; CT, computed tomography; MRI, 
magnetic resonance imaging. 
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Table 2. The current status to screen for and diagnose HCC in China 
 
Items Current status in China Ref. 
Prevalence The second most common cancer in urban areas and most 
common in rural areas; with an overall prevalence rate of 
26-32/10,000, even up to 70-80/10,000 in some areas 
(3, 4) 
Mortality The second leading cause of cancer-related deaths in males and 
the third leading cause of cancer-related deaths in females; with a 
total mortality rate of 26.26/100,000 
(33) 
Etiological factors 85% of patients with HBV infection, 10% of patients with HCV 
infection, and a small minority involve HBV and HCV 
(3, 4) 
Major at-risk population People with HBV infection; 93 million HBV carriers, 20 million 
of these with chronic HBV infection 
(33, 34) 
Screening and Diagnostic 
algorithm 
The test of ultrasonography and AFP every 6 months for the 
population ages 35-40 at risk for developing HCC 
(10, 31) 
Treatment algorithm Comprehensive therapy predominantly in the form of surgery (35) 
Early detection Most patients with HCC present with advanced-stage disease (10, 36) 
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are higher than those for either marker alone (32, 42-46). Furthermore, several studies have 
showed the potential clinical usefulness of DCP as a preoperative indicator in assessing 
HCC progression and could also benefit post-treatment monitoring (47-51). 
In Japan, DCP and AFP are widely and routinely used as serum biomarkers in 
HCC early diagnosis, which benefit more than 60% of patients that could be detected in the 
early stage (52), besides, using DCP as an indicator for HCC recurrence and post-treatment 
monitoring have also been widely used in clinical practice. However, DCP was just widely 
used in clinical practice in Japan and South Korea (53), yet has not been widely used 
clinically in China until now. Furthermore, unlike in Japan and Western countries, the main 
etiological factor for HCC in China is chronic infection with HBV, which accounts for 85% 
of all cases (3, 4). In order to assess the diagnostic value of DCP in Chinese patients with 
HCC, two studies published in 2002 (involving 60 patients with HCC and 30 patients with 
cirrhosis) (54) and 2003 (involving 120 patients with HCC and 90 patients with cirrhosis) 
(55) have indicated that the combined testing of DCP and AFP had a sensitivity of 78.3%, 
which is higher than that for DCP or AFP alone. However, the published studies were small 
in scale, and the prognostic value of DCP in Chinese patients predominantly caused by 
HBV infection has not been identified. Thus, the multiple-center studies of larger pools of 
serum samples from patients with HCC need to be conducted to provide further validation. 
Given the rising incidence of HCC in China and the lack of substantial data on 
DCP’s role as a serum biomarker in HCC diagnosis and prognosis for Chinese patients 
predominantly caused by HBV infection, we conducted this large-scale, multi-center 
case-controlled study to further investigate the clinical effectiveness of serum biomarker 
DCP for Chinese patients with HCC. 
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2. Patients and methods 
 
2.1. Study population 
 
The subject pool consisted of 1,153 cases from the Hepato-Biliary-Pancreatic Surgery 
Division at the Southwest Hospital of the Third Military Medical University, the Tianjin 
Medical University Cancer Hospital, and the 302 Military Hospital of China between 2001 
and 2012 (Figure 2). This study was approved by institutional review boards, and 
clinicopathological information on each subject was collected.  
Five groups of subjects were enrolled: 1) HCC group, which involved HCC 
patients proved by pathology after hepatic resection; 2) Malignant disease group, which 
involved patients with non-HCC malignant disease of the liver, bile ducts, or pancreas, 
including carcinoma of the gallbladder, cholangiocarcinoma, and pancreatic carcinoma 
underwent surgery; 3) Benign disease group, which involved patients with benign disease 
of the liver, bile ducts, or pancreas, including cholangiolithiasis, cholecystitis, and hepatic 
cysts underwent surgery; 4) Chronic liver disease group, which involved patients with 
progressivity of hepatitis or liver cirrhosis; and 5) Normal group, which involved normal 
healthy subjects without finding of abnormity index by laboratory examination and imaging 
examination. None of cases in 5 groups received warfarin or other vitamin K inhibitor 
during the week prior to blood samples collection.  
For patients in HCC group, HCC was clinically diagnosed based on the Chinese 
clinical guideline of HCC (10) and pathologic findings from resected specimens were 
confirmed for each patient. Information on demographic data and tumor characteristics 
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Figure 2. The source of subject pool in the present study.  
 
The subject pool of 1,153 cases were from the Hepato-Biliary-Pancreatic Surgery Division 
at the Southwest Hospital of the Third Military Medical University in Chongqing, the 
Tianjin Medical University Cancer Hospital in Tianjin, and the 302 Military Hospital of 
China in Beijing between 2001 and 2012. All testing was conducted at the Southwest 
Hospital of the Third Military Medical University in Chongqing by the same group of 
laboratory technicians. 
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were recorded for each patient. No patients had received any previous therapy to treat HCC 
such as TACE, RFA, percutaneous ethanol injection (PEI), or resection and they underwent 
surgery for the first time at the Hospital. A detailed clinical evaluation was done before 
surgery for all patients.  
For patients in Malignant disease group and Benign disease group, patients were 
diagnosed with either benign or malignant diseases of the liver, bile ducts, or pancreas other 
than HCC based on laboratory examination, imaging findings including those from 
ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), as well as 
pathologic findings from resected specimens. Detailed diagnostic information was also 
recorded. All of the patients with HCC and patients without HCC were treated depending 
on their condition and stage of their disease. 
For patients with progressivity of hepatitis or liver cirrhosis in Chronic liver 
disease group, HBV infection was diagnosed based on a positive result for hepatitis B 
surface antigen (HBsAg), and HCV infection was confirmed based on a positive result for 
anti-HCV and HCV RNA.  
 
2.2. Blood samples 
 
For patients in HCC group, Malignant disease group and Benign disease group, a 2-mL 
sample of peripheral blood was obtained within a week before surgery and immediately 
centrifuged into serum and plasma. Blood samples were also obtained from patients in 
Chronic liver disease group and healthy subjects in Normal group at the time of enrollment. 
The samples of serum and plasma were stored in aliquots in a refrigerator at -80°C until 
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testing. 
 
2.3. Serological detection of DCP and AFP 
 
Serum DCP levels were measured with an electrochemiluminescence immunoassay using a 
highly sensitive DCP determination kit (ED036, Eisai, Tokyo, Japan) in accordance with 
the manufacturer's instructions. The assay principle was showed in Figure 3. The range of 
detection was 10.00-200,000.00 mAU/mL. Serum AFP levels were tested using a 
commercial ELISA kit in accordance with instructions from the manufacturer (Biocell 
Biotech, Zhengzhou, China).  
All testing was conducted at the Southwest Hospital of the Third Military Medical 
University by the same group of laboratory technicians, and none of technicians was 
informed of the subject’s status prior to testing. 
 
2.4. Data collection and analysis 
 
For 1,153 cases, the clinicopathological variables of age, gender, HBsAg, anti-HCV, levels 
of DCP and AFP, tumor size, and histological pathology were examined. To investigate the 
relationship between DCP expression and the prognosis for Chinese patients with HCC, the 
variables of tumor number, tumor differentiation, microvascular invasion, satellite node, 
and TNM stage from112 HBV-related HCC cases were also collected. 
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Figure 3. The assay principle of DCP (PIVKA-II).  
 
Serum DCP levels were measured with an electrochemiluminescence immunoassay using a 
highly sensitive DCP determination kit (ED036, Eisai, Tokyo, Japan) in accordance with 
the manufacturer's instructions. The range of detection was 10.00-200,000.00 mAU/mL, 
using the two-step method of sandwich method. B/F, Bound/Free Separation; ALP, Alkaline 
phosphatase; ALP Conjugate, ALP labeled anti-prothrombin antibody; AMPPD, 
3-(2‘-spiroadamantane)-4-methoxy-4-(3”-phosphoryloxy) phenyl-1,2-dioxetane salt. 
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Continuous variables were expressed as median (range) and compared between 
groups using the Wilcoxon rank-sum test. Categorical data were compared using the χ2 test. 
Descriptive statistics for the transformed marker were compared using box plots and then 
using analysis of variance. Youden’s index was calculated as an index of sensitivity and 
specificity.  
To determine the optimal cut-off values for DCP and AFP to diagnose HCC, 
receiver operating characteristic (ROC) curves were created using all possible cut-offs for 
each assay. The area under ROC curves (AUROC) were also been calculated. A bivariate 
normal distribution for the two markers was assumed. A 2-tailed P value of < 0.05 was 
used to determine statistical significance.  
To ascertain the prognostic value of DCP in Chinese patients with HCC 
predominantly caused by HBV infection, survival curves were calculated using the 
Kaplan-Meier method and compared to the results of the log-rank test. All variables that 
had P value of < 0.05 in univariate analysis were selected for multivariate analysis, which 
was performed using Cox’s proportional-hazards model. 
All statistical analyses were performed using the statistical software package 
SPSS® version 22.0 for Windows® (SPSS, Chicago, Illinois, USA). 
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3. Results 
 
3.1. Clinical utility of simultaneous measurement of DCP and AFP in diagnosing 
patients with HCC among a total of 1,153 subjects 
 
3.1.1. Baseline characteristics 
 
As shown in Table 3, there were 550 cases in HCC group, 164 in Malignant disease group, 
181 in Benign disease group, 85 in Chronic liver disease group, and 173 in Normal group. 
Among a total of 1,153 cases, 876 cases (75.98%) were male and 277 (24.02%) 
were female, with a median age of 46 years (range: 12-83 years). 
For the 550 patients with HCC, 74.18% (408 patients) were infected with HBV, 
which was significantly higher than that in patients with malignant disease and patients 
with benign disease (P < 0.001). Chronic liver disease group included 79 patients who were 
positive for HBsAg. Of 1,153 subjects in total, only 17 patients were positive for anti-HCV 
antibodies (10 cases in HCC group, 1 in Benign disease group, and 6 in Chronic liver 
disease group).  
 
3.1.2. Results of DCP and AFP measurement 
 
The median levels of DCP and AFP in patients with HCC were 516.50 mAU/mL (range: 
10.00-200,000.00 mAU/mL) and 237.40 ng/mL (range: 0.24-1,939,000.00 ng/mL), which  
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Table 3. Laboratory results for five groups of subjects 
Items 
HCC 
group 
(n = 550) 
Malignant 
Disease group
(n = 164) 
Benign disease
group 
(n = 181*) 
Chronic liver 
disease group 
(n = 85) 
Normal 
group 
(n = 173) 
P** 
Age (year) 
median (range) 
51 (15-82) 56 (31-83) 50 (12-83) 32 (22-46) 28 (21-46)  
Gender 
(male / female) 
480 / 70 110 / 54 84 / 97 70 / 15 132 / 41  
HBsAg      < 0.001
positive (cases) 408 43†a 44†b 79 0  
Anti-HCV       
positive (cases) 10 0 1‡ 6 0  
DCP level 
(mAU/mL) 
     < 0.001
median 516.50 27.93 20.00 48.78 29.91  
minimum < 10.00 < 10.00 < 10.00 22.20 < 10.00  
maximum > 200,000.00 48,193.50 129,297.83 178.78 104.97  
AFP level 
(ng/mL) 
     < 0.001
median 237.40 2.81 2.30 7.00 6.00  
minimum 0.24 0.20 0.20 1.00 0.00  
maximum 1,939,000.00 3,098.00 1,082.20 25.00 30.00  
* HBsAg results were missing for 11 patients; †a including 6 patients with HBV-related cirrhosis proven by pathology, †b 
including 20 patients with HBV-related cirrhosis proven by pathology; ‡ including 1 patients with HCV-related cirrhosis 
proven by pathology. ** patients with HCC vs. the other four groups of subjects, respectively. 
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were significantly higher than those in the other four groups of subjects (P < 0.001) (Table 
3). There was no significant correlation between serum levels of DCP and AFP (R2 = 0.154) 
(Figure 4).  
When a cut-off value of 40 mAU/ml for DCP, reported to be the upper limit of 
normal for Japanese subjects (56), was used, 82.91% of patients in HCC group, 38.31% of 
patients in Malignant disease group, 27.75% of patients in Benign disease group, 61.18% of 
patients in Chronic liver disease group, and 34.68% of subjects in Normal group had 
elevated DCP levels.  
When using a cut-off value of 10 ng/mL for AFP as the upper limit of normal 
reported in Chinese subjects, 74.80% of patients in HCC group, 20.83% of patients in 
Malignant disease group, 12.50% of patients in Benign disease group, 28.24% of patients in 
Chronic liver disease group, and 30.06% of subjects in Normal group had elevated AFP 
levels (Figure 5). 
 
3.1.3. Optimal cut-off values for DCP and AFP in differentiating patients with HCC 
from the other four groups of subjects studied 
 
In order to determine optimal cut-off values that could balance the false-positive rate and 
the false-negative rate with the best positive predictive value (PPV) and negative predictive 
value (NPV) that could best distinguish patients with HCC from the other four groups of 
subjects, ROC curves were plotted for DCP and for AFP.  
As shown in Figure 6, the optimal cut-off value for DCP was 86 mAU/ml, which  
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Figure 4. The correlation between serum levels of DCP and AFP.  
 
Serum levels of DCP and AFP were plotted and their relation was compared. The median 
levels of DCP and AFP in patients with HCC were 516.50 mAU/mL (range: 
10.00-200,000.00 mAU/mL) and 237.40 ng/mL (range: 0.24-1,939,000.00 ng/mL). There 
was no significant correlation between serum levels of DCP and AFP (R2 = 0.154). 
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Figure 5. Scatter plot for DCP levels (A) and AFP levels (B) in 5 groups of subjects. 
 
When a cut-off value of 40 mAU/ml for DCP, reported to be the upper limit of normal for 
Japanese subjects, was used, 82.91% of patients in HCC group had elevated DCP levels. 
When using a cut-off value of 10 ng/mL for AFP as the upper limit of normal reported in 
Chinese subjects, 74.80% of patients in HCC group had elevated AFP levels. 
22 
 
 
 
Figure 6. ROC curves comparing DCP and AFP levels in patients with HCC vs.  
patients without HCC.  
 
The curves show an optimal cut-off value for DCP of 86 mAU/mL and for AFP of 21 
ng/mL. The AUROC was 0.846 for DCP, 0.832 for AFP, and 0.890 for the combination of 
DCP and AFP. RCO, receiver-operating characteristic; AUROC, area under the ROC curve. 
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yielded a sensitivity of 71.50% and specificity of 86.30% in differentiating patients with 
HCC from the other four groups of subjects; the optimal cut-off value for AFP was 21 
ng/mL, which yielded a sensitivity of 68.00% and specificity of 93.20% in differentiating 
patients with HCC from the other four groups of subjects. The AUROC was 0.846 (95% CI, 
0.794-0.863, P < 0.001) for DCP, 0.832 (95% CI, 0.817-0.879, P < 0.001) for AFP, and 
0.890 (95% CI, 0.869- 0.911, P < 0.001) for the combination of DCP and AFP. 
When using DCP with the cut-off value of 86 mAU/ml, 71.45% of patients in 
HCC group, 22.08% of patients in Malignant disease group, 15.61% of patients in Benign 
disease group, 11.76% of patients in Chronic liver disease group, and 5.20% of subjects in 
Normal group had elevated DCP levels.  
When using AFP with the cut-off value of 21 ng/mL, 68.01% of patients in HCC 
group, 9.03% of patients in Malignant disease group, 7.29% of patients in Benign disease 
group, 3.53% of patients in Chronic liver disease group, and 5.20% of subjects in Normal 
group had elevated AFP levels. 
 
3.1.4. Sensitivity, specificity, and predictive values of DCP and AFP in differentiating 
patients with HCC from the other four groups of subjects studied 
 
As shown in Table 4, DCP with a cut-off value of 86 mAU/mL had a high specificity and 
PPV but a lower sensitivity and NPV than a cut-off value of 40 mAU/mL. The Youden 
index for DCP with a cut-off value of 86 mAU/mL was 49.40% (HCC group vs. Malignant 
disease group), 55.90% (HCC group vs. Benign disease group), 58.70% (HCC group vs.  
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Table 4. The clinical utility of DCP and AFP with different cut-off values in differentiating HCC 
patients from other groups of subjects 
DCP / AFP (cut-off value)  Sensitivity(%) 
Specificity
(%) 
PPV 
(%) 
NPV 
(%) 
Youden 
Index (%)
DCP (86 mAU/mL)      
HCC group vs. Malignant disease group 71.50 77.90 92.04 43.32 49.40 
HCC group vs. Benign disease group 71.50 84.40 93.57 48.18 55.90 
HCC group vs. Chronic liver disease group 71.50 88.20 97.52 32.33 58.70 
  HCC group vs. Normal group 71.50 94.80 97.76 51.09 66.30 
      
DCP (40 mAU/mL)      
   HCC group vs. Malignant disease group 82.90 61.70 88.54 50.26 44.60 
   HCC group vs. Benign disease group 82.90 72.30 90.48 57.08 45.20 
HCC group vs. Chronic liver disease group 82.90 38.80 89.76 25.98 21.70 
   HCC group vs. Normal group 82.90 65.30 88.37 54.59 48.20 
      
AFP (10 ng/mL)      
   HCC group vs. Malignant disease group 74.80 79.00 92.52 47.48 53.80 
   HCC group vs. Benign disease group 74.80 87.50 96.87 40.19 62.30 
HCC group vs. Chronic liver disease group 74.80 71.80 93.92 32.80 46.60 
   HCC group vs. Normal group 74.80 69.90 87.71 49.19 44.70 
      
AFP (21 ng/mL)      
   HCC group vs. Malignant disease group 68.00 91.00 96.30 45.17 59.00 
   HCC group vs. Benign disease group 68.00 92.70 97.97 35.89 60.70 
HCC group vs. Chronic liver disease group 68.00 96.50 99.12 34.02 64.50 
   HCC group vs. Normal group 68.00 94.80 97.40 50.77 62.80 
      
AFP (400 ng/mL)      
   HCC group vs. Malignant disease group 45.10 97.20 98.25 33.90 42.30 
   HCC group vs. Benign disease group 45.10 99.00 99.56 25.82 44.10 
HCC group vs. Chronic liver disease group 45.10 100.00 100.00 23.74 54.90 
   HCC group vs. Normal group 45.10 100.00 100.00 38.79 54.90 
      
AFP (21 ng/mL) + DCP (86 mAU/mL)      
   HCC group vs. Malignant disease group 82.90 75.20 91.93 56.28 58.10 
   HCC group vs. Benign disease group 82.90 82.30 93.44 61.32 65.20 
HCC group vs. Chronic liver disease group 82.90 84.70 97.23 43.37 67.60 
HCC group vs. Normal group 82.90 90.80 96.61 62.55 73.70 
PPV, positive predictive value; NPV, negative predictive value. 
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Chronic liver disease group), and 66.30% (HCC group vs. Normal group), which were 
higher than that of DCP with cut-off value of 40 mAU/mL. 
 As the cut-off AFP value increased from 10 ng/mL to 400 ng/mL, its specificity 
and PPV increased but its sensitivity and NPV decreased. The Youden index for AFP with 
a cut-off value of 21 ng/mL was 59.00% (HCC group vs. Malignant disease group), 60.70% 
(HCC group vs. Benign disease group), 64.50% (HCC group vs. Chronic liver disease 
group), and 62.80% (HCC group vs. Normal group), which were higher than those for AFP 
with a cut-off value of 10 ng/mL or 400 ng/mL. The combination of DCP with a cut-off 
value of 86 mAU/ml and AFP with a cut-off value of 21 ng/mL had a greater sensitivity 
and a higher Youden index than DCP or AFP alone in differentiating patients with HCC 
from the other four groups of subjects, regardless of other cut-off value chosen. 
 
3.1.5. DCP and AFP levels for patients with HCC according to tumor size 
 
As shown in Table 5, the median DCP level increased from 93.91 mAU/mL to 2,014.00 
mAU/mL along with the enlargement of tumor size. For patients with a tumor > 10.0 cm, 
the median AFP level was 2,265.00 ng/mL, which was significantly higher than that in 
patients with a smaller tumor. 
Among the 550 patients with HCC, 41 cases were with the tumor size of ≤ 2.0 cm, 
with the median values for DCP as 93.01 mAU/mL (range: 10-7,369.15 mAU/mL), and for 
AFP as 216.10 ng/mL (range: 0.24-59,615.00 ng/mL); 99 cases were with the tumor size of 
≤ 3.0 cm, the median values for DCP as 134.59 mAU/mL (range: 10-46,825.61 mAU/mL), 
and for AFP as 297.63 ng/mL (range: 0.24-1,647,080.00 ng/mL); 205 cases were with the 
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tumor size of ≤ 5.0 cm, the median values for DCP as 280.87 mAU/mL (range: 10-200,000 
mAU/mL), and for AFP as 206.40 ng/mL (range: 0.24-1,647,080.00 ng/mL). 
 
3.1.6. The sensitivity of DCP and AFP in diagnosing patients with HCC according to 
tumor size 
 
As shown in Table 6, the sensitivity of DCP with a cut-off value of 86 mAU/ml increased 
from 53.66% to 86.00% along the enlargement of tumor size. The combination of DCP 
with a cut-off value of 86 mAU/ml and AFP with a cut-off value of 21 ng/mL resulted in a 
sensitivity of approximately 90%, which was significantly higher than that of DCP or AFP 
alone.  
For 41 cases with the tumor size of ≤ 2.0 cm, the combination of DCP with a 
cut-off value of 86 mAU/ml and AFP with a cut-off value of 21 ng/mL resulted in a 
sensitivity of 92.68%, which was higher than that of DCP (53.66%) or AFP (80.49%) alone 
(P < 0.001). For 99 cases with the tumor size of ≤ 3.0 cm, the combination of DCP and 
AFP with those cut-off values resulted in a sensitivity of 89.90%, which was higher than 
that of than that of DCP (62.63%) or AFP (77.78%) alone (P < 0.001). For 205 cases with 
the tumor size of ≤ 5.0 cm, the combination of DCP and AFP with those cut-off values 
resulted in a sensitivity of 88.78%, which was also higher than that of than that of DCP 
(68.78%) or AFP (67.80%) alone (P < 0.001). 
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Table 5. DCP and AFP levels in 550 patients with HCC according to tumor size 
Size of tumor 
Median Minimum Maximum 
DCP 
(mAU/mL) 
AFP 
(ng/mL) 
DCP 
(mAU/mL) 
AFP 
(ng/mL) 
DCP 
(mAU/mL) 
AFP 
 (ng/mL) 
≤ 2.0 cm   93.91   216.10 < 10.00 0.24  7,369.15   59,615.00
> 2.0 cm, ≤ 3.0 cm  191.82   391.93 < 10.00 1.83 46,825.61 1,647,080.00
> 3.0 cm, ≤ 4.0 cm  462.78   126.90 < 10.00 1.38 > 200,000.00  366,417.00
> 4.0 cm, ≤ 5.0 cm  556.88   174.00 < 10.00 0.82 111,170.15 1,193,000.00
> 5.0 cm, ≤ 10.0 cm 1,278.91   200.00 < 10.00 0.24 > 200,000.00  794,800.00
> 10.0 cm 2,014.00 2,265.00 < 10.00 1.00 > 200,000.00 1,939,000.00
 
 
 
Table 6. The sensitivity of DCP and AFP in the diagnosis of 550 patients with HCC according to 
tumor size 
Size of tumor 
DCP (86 mAU/mL)  
(%) 
AFP (21 ng/mL) 
(%) 
DCP (86 mAU/mL) + AFP (21 ng/mL) 
(%) 
≤ 2.0 cm 53.66 80.49 92.68 
> 2.0 cm, ≤ 3.0 cm 69.00 75.90 87.90 
> 3.0 cm, ≤ 4.0 cm 76.50 58.80 88.20 
> 4.0 cm, ≤ 5.0 cm 72.70 58.20 87.30 
> 5.0 cm, ≤ 10.0 cm 80.50 65.80 88.40 
> 10.0 cm 86.00 79.10 94.20 
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3.2. Relation between DCP expression and the prognosis for Chinese patients with 
HCC 
 
3.2.1. General information 
 
In order to ascertain the prognostic value of DCP in Chinese patients with HCC, we made a 
further analysis on 112 patients with HBV-related HCC who underwent surgical resection 
at the Hepato-Biliary-Pancreatic Surgery Division of Tianjin Medical University Cancer 
Hospital from February 2008 to October 2011. The date of prognosis for other patients with 
HCC that enrolled in the present study is now in collection. 
Among 112 HCC cases, 95 were male and 17 were female with a median age of 54 
years (range: 21-81 years),79 cases (70.54%) with the tumor size of > 3.0 cm, 90 cases 
(80.36%) with a single tumor, 67 cases (59.82%) with moderately differentiated tumor, 73 
cases (65.18%) present microvascular invasion, 28 cases (25.00%) present satellite nodes, 
33 cases (29.46%) with a more advanced TNM stage, and 52 cases (46.43%) present tumor 
recurrence (Table 7). 
 
3.2.2. Serum DCP level and its relationship to clinicopathological characteristics 
 
Serum DCP level was determined in each of the 112 HCC patients, with a median value of 
468.56 mAU/mL (range: 10.00-200,000.00 mAU/mL). Seventy-five of 112 patients 
(66.96%) showed serum DCP level of > 86 mAU/mL, which was identified as the optimal 
cut-off value in differentiating patients with HCC from the other four groups of subjects in  
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Table 7. Serum DCP level and clinicopathological characteristics in 112 patients with HBV-related HCC 
*Showed statistically significant difference between the patients in poorly differentiated tumor group and the 
patients in well differentiated tumor group. 
  
Clinicopathological variables 
DCP > 86 mAU/mL 
cases / total cases (%) 
P value 
Tumor size 
      ≤ 3.0 cm 
      > 3.0 cm 
 
15 / 33 (45.45%) 
60 / 79 (75.95%) 
 
0.002 
Tumor number 
      single 
      multiple 
 
57 / 90 (63.33%) 
18 / 22 (81.82%) 
 
0.085 
Tumor differentiation 
      well 
      moderate 
      poor 
 
10 / 19 (52.63%) 
46 / 67 (68.66%) 
19 / 26 (73.08%) 
 
0.039* 
Microvascular invasion 
      absent 
      present 
 
 9 / 39 (23.08%) 
34 / 73 (46.58%) 
0.013 
Satellite nodes 
      absent 
      present 
 
53 / 84 (63.09%) 
22 / 28 (78.57%) 
 
0.132 
TNM stage 
      I+II 
      III+IV 
 
48 / 79 (60.76%) 
27 / 33 (81.82%) 
 
0.031 
Recurrence 
      absent 
      present 
 
35 / 60 (58.33%) 
40 / 52 (76.92%) 
 
0.035 
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this study, and 37 of 112 patients (33.04%) showed DCP level of ≤ 86 mAU/mL. 
 As shown in Table 7, high serum DCP levels were significantly frequent in 
patients who were with larger tumor size (> 3.0 cm vs. ≤ 3.0 cm: 75.95% vs. 45.45%, P = 
0.002), poorly differentiated tumor (poor vs. well: 73.08% vs. 52.63%, P = 0.039), presence 
of microvascular invasion (presence vs. absence: 46.58% vs 23.08%, P = 0.013), with a 
more advanced TNM stage (III+IV vs. I+II: 81.82% vs. 60.76%, P = 0.031), or presence of 
tumor recurrence (presence vs. absence: 76.92% vs. 58.33%, P = 0.035).  
Besides, although the rate of patients with DCP > 86 mAU/mL was higher in 
multiple tumor group (81.82%) than that in single tumor group (63.33%), and higher in 
presence of satellite node group (78.57%) than that in absence of satellite node group 
(63.09%), there was no significantly statistic difference between the two groups, 
respectively. 
 
3.2.3. The relationship between serum DCP level and postoperative survival 
 
The relationship between high or low serum DCP levels (cut-off levels at 86 mAU/mL) and 
patient survival was analyzed. As shown in Figure 7, HCC patients with high serum DCP 
level showed significantly poorer prognosis than those with low serum DCP levels: 3-year 
survival rates were 54.53% and 81.82%, respectively, as determined by the Kaplan-Meier 
method (P = 0.007 by the log-rank test). 
Results of univariate analysis indicated that the 3-year survival was also 
significantly worse in patients with larger tumor size (> 3.0 cm vs. ≤ 3.0 cm: 64.02% vs. 
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Figure 7. The curves of survival for 112 patients with HBV-related HCC according to 
serum DCP with cut-off value of 86 mAU/mL.  
 
HCC patients with serum DCP level of > 86 mAU/mL showed significantly poorer 
prognosis than patients with serum DCP level of ≤ 86 mAU/mL (3-year survival rates: 
54.53% vs. 81.82%, P = 0.007). 
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93.11%, P = 0.020), the presence of microvascular invasion (presence vs. absence: 61.02% 
vs. 85.91%, P = 0.022), a more advanced TNM stage (III+IV vs. I+II: 51.92% vs. 80.71%, 
P < 0.001), and the presence of tumor recurrence (present vs. absent: 50.23% vs. 78.45%, P 
= 0.008) (Table 8). 
The 3-year survival rate of patients was not significantly different in the 
classification of serum AFP level (≤ 21 ng/mL vs. > 21 ng/mL: 72.56% vs. 67.23%), tumor 
number (single vs. multiple: 74.64% vs. 62.23%), satellite node (absence vs. presence: 
73.43% vs. 70.52%) and tumor differentiation (well vs. moderate vs. poor: 82.80% vs. 
71.91% vs. 68.43%).  
All of above items with P < 0.05 in the univariate analysis were selected as 
variables for inclusion in the multivariate regression analysis by using Cox proportional 
hazard model. As shown in Table 9, after multivariate analysis, DCP > 86 mAU/mL (HR: 
2.165, 95% CI: 1.048-4.521, P = 0.047), the presence of microvascular invasion (HR: 1.742, 
95% CI: 1.016-4.326, P = 0.048) and a more advanced TNM stage (HR: 2.316, 95% CI: 
1.125-4.770, P = 0.023) were identified as statistically significant risk factors for 3-year 
survival. 
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Table 8. Univariate analysis on risk factors of 3-year survival for112 patients with HBV-related HCC  
Variables cases 3-year survival rates (%) P value 
Serum DCP level 
      ≤ 86 mAU/mL 
> 86 mAU/mL 
 
37 
75 
 
81.82 
54.53 
 
0.007 
Serum AFP level 
      ≤ 21 ng/mL 
> 21 ng/mL 
 
41 
71 
 
72.56 
67.23 
 
0.112 
Tumor size 
      ≤ 3.0 cm 
      > 3.0 cm 
 
33 
79 
 
93.11 
64.02 
 
0.020 
Tumor number 
      single 
      multiple 
 
90 
22 
 
74.64 
62.23 
 
0.132 
Tumor differentiation 
      well 
      moderate 
      poor 
 
19 
67 
26 
 
82.80 
71.91 
68.43 
 
0.251 
Microvascular invasion 
      absent 
      present 
 
69 
43 
 
85.91 
61.02 
 
0.022 
Satellite nodes 
      absent 
      present 
 
84 
28 
 
73.43 
70.52 
 
0.139 
TNM stage 
      I+II 
      III+IV 
 
79 
33 
 
80.71 
51.92 
 
< 0.001 
Recurrence 
      absent 
      present 
 
60 
52 
 
78.45 
50.23 
 
0.008 
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Table 9. Multivariate analysis on risk factors of 3-year survival for112 patients with HBV-related HCC  
Variables Hazard ratio (95% CI) P value 
Serum DCP level 
      ≤ 86 mAU/mL vs. > 86 mAU/mL  
 
2.165 (1.048-4.521) 
0.047 
Microvascular invasion 
      absent vs. present 
 
1.742 (1.016-4.326) 
0.048 
TNM stage 
      I+II vs. III+IV 
 
2.316 (1.125-4.770) 
0.023 
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4. Discussion 
 
The present study is the first large-scale, multi-center case-controlled research conducted in 
China to investigate the clinical effectiveness of serum biomarker DCP for Chinese patients 
with HCC predominantly caused by HBV infection. Results indicated that DCP could be a 
good candidate as a compliment to AFP in diagnosing Chinese patients with HCC, with a 
sensitivity of approximately 90% for the combined testing of DCP and AFP, even for small 
tumor size. Besides, the relation between DCP expression and the prognosis for Chinese 
patients with HCC has also been confirmed by the present study, which suggested that 
serum DCP could serve as a preoperative indicator in assessing progression for Chinese 
patients with HCC.  
Furthermore, this study not only provided evidence on the clinical effectiveness of 
serum DCP in HCC diagnosis and prognosis for Chinese patients with HCC, but also 
promoted DCP to be used in actual clinical practice. With the impetus of this Japan-China 
joint research project, currently, DCP has been used in actual clinical practice in some 
hospitals of China since DCP approved to be used in China in 2014. With the increased 
application in clinical practice, the test of DCP is expected to be routinely used to improve 
clinical outcomes for patients with HCC in China. 
In China, HCC has currently become the second leading cause of cancer-related 
deaths in men and the third leading cause of such deaths in women, and its incidence has 
increased in the past few decades as a result of the high prevalence of its main etiological 
factor, chronic HBV infection (3, 4). People with HBV infection are the largest population 
at risk of developing HCC in China. In fact, 93 million HBV carriers are Chinese, 
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accounting for 2/3 of such patients worldwide, and about 20 million of these people have 
chronic HBV infection (33, 34). Evidence has shown that surgical resection and liver 
transplantation may offer the best opportunity for treating HCC yet are only available to 
early-detected patients (5, 6, 8, 9). During the past decades, as clinical techniques have 
developed in China, new techniques in treatment have also become available, such as 
laparoscopic surgery and minimally invasive robotic surgery. However, most HCC patient 
in China still suffered from advanced-stage disease, thus reducing the chance of curable 
treatment (57, 58). Therefore, strategies to diagnose HCC at an earlier stage are urgently 
needed in China when curable interventions can be offered to achieve long-term 
disease-free survival for Chinese patients with HCC. 
The diagnosis tools should have an acceptable accuracy, accessibility, and 
affordability. In general, the tests used to diagnose HCC around the world include imaging 
diagnosis, serological diagnosis, and histological diagnosis. Among of them, a biopsy (also 
known as fine needle aspiration cytology, FNAC) has an overall sensitivity and specificity 
of 95.2% and 100%, but biopsy tests should be avoided if curative surgery is planned 
because the chance of needle track tumor seeding following a biopsy is 2.7% unless such a 
biopsy might change management of the patient or the major diagnostic doubt persists that 
cannot be resolved with imaging techniques or serological diagnosis (10).  
Diagnostic imaging techniques include ultrasonography, computed tomography 
(CT), and magnetic resonance imaging (MRI), with a respective sensitivity of 60% (95% 
CI: 44-76%), 68% (95% CI: 55-80%) and 81% (95% CI: 70-91%) and a respective 
specificity of 97% (95% CI: 95-98%), 93% (95% CI: 89-96%) and 85% (95%CI: 77-93%) 
(10, 31, 33). Currently, ultrasound is the most common imaging tool used in HCC 
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diagnosis in China thanks to its features of simple, inexpensive, non-invasive, and allows 
real-time observation. However, the successful ultrasound detection relies on the available 
of ultrasound equipment, the expertise of the physician, and the echo texture of the liver. So 
the actual sensitivity and specificity of ultrasonography is difficult to evaluate due to the 
lack of standard in China.  
Serum biomarkers are attractive potential tools for HCC early diagnosis because 
they would enable non-invasive, objective, and reproducible assessments (59). According 
to the Chinese Guidelines on HCC, serum AFP measurement and ultrasonography are 
recommended to be performed every 6 months for the people ages between 35 and 40 at 
risk for developing HCC (21). However, it should be noted that the disadvantage of low 
sensitivity, low specificity, and limited accuracy for AFP in detecting small HCC diminish 
its clinical utility in HCC early diagnosis (37-41). Thus, other reliable serum biomarkers 
need to be identified to complement AFP in order to improve clinical outcomes for patients 
with HCC in China. 
Recent years have also seen many studies on the clinical usefulness of other serum 
biomarkers in detecting HCC early, including Golgi protein-73 (GP73), glypican-3 (GPC3) 
and gamma-glutamyltransferase (GGTII). Most recently, research on Dickkopf-1 (DKK1) 
and Midkine (MDK) as diagnostic serum biomarkers has garnered interest, which 
suggested that the novel serum biomarkers DKK1 and MDK can augment the measurement 
of AFP when diagnosing HCC, and particularly when diagnosing patients who are negative 
for AFP and/or who have HCC in an early stage (60, 61). However, these studies were 
small in scale and involved few patient, more such studies are needed before they can be 
included as valid biomarkers in strategies to diagnose patients who present with liver 
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masses. By contrast, the clinical usefulness of serum DCP in HCC diagnosis has been 
confirmed by a series of studies in many countries, especially in Japan and some Western 
countries, where HCC is predominantly caused by HCV infection. 
DCP is an abnormal prothrombin that lacks carboxylation of specific 
amino-terminal glutamic acid residues. Since Liebman et al. found DCP to be a useful 
serum marker in diagnosing HCC in 1984 (62), differences in the sensitivity and specificity 
of DCP and AFP have been extensively discussed (Table 10) (42, 43, 54, 55, 63-74). In 8  
large case-controlled studies, serum DCP was found to have a sensitivity of 48-62%, a 
specificity of 81-98%, and a diagnostic accuracy of 59-84% in differentiating patients with 
HCC from those with cirrhosis; in comparison, serum AFP was found to have a sensitivity 
of 40-54%, a specificity of 88-97%, and a diagnostic accuracy of 64-76% (45, 75). 
Although several studies of the two tumor markers have been reported, results of those 
studies conflicted with regard to the relative performance of those markers. Some studies 
showed that DCP has greater sensitivity than AFP, while other studies found no significant 
difference in the sensitivity of the two serum markers, but the combination of DCP and AFP, 
however, appeared to have greater sensitivity than either marker alone (70, 75-77). These 
differences may be due to the use of different marker cut-off values in each study (40, 80, 
100 mAU/mL or higher value for DCP and 10-400 ng/mL for AFP), differences in 
underlying liver disease, tumor stage, or other aspects. 
The clinical utility of DCP in diagnosing HCC at a reference level of 40 mAU/mL 
has been established by a number of retrospective and prospective studies (78). However, 
most of these studies were completed in Japan or Western counties, where HCC is 
predominantly caused by HCV infection (78-80). In Japan, more than 70% of patients with 
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Table 10. The exploration of clinical usefulness of using serum biomarker DCP to complement AFP in 
HCC early detection* 
Marker Cut-off value Sensitivity Specificity Ref. 
DCP + AFP 8 mAU/mL, 20 ng/mL 90.0% (90/100) N (63) 
DCP + AFP 16 mAU/mL, 20 ng/mL 87.3% (55/63) 84.0% (158/188) (64) 
DCP + AFP 40 mAU/mL, 20 ng/mL 83.5% (76/91) N (65) 
DCP + AFP 40 mAU/mL, 20 ng/mL 86.7% (52/60) N (66) 
DCP + AFP 40 mAU/mL, 20 ng/mL 78.3% (94/120) 58.9% (53/90) (55) 
DCP + AFP 40 mAU/mL, 20 ng/mL 83.6% (51/61) 68.2% (45/66) (67) 
DCP + AFP 40 mAU/mL, 20 ng/mL 83.3% (204/245) 77.2% (206/267) (68) 
DCP + AFP 40 mAU/mL, 200 ng/mL 78.3% (83/106) N (69) 
DCP + AFP 80 mAU/mL, 40 ng/mL 65.5% (19/29) 84.5% (596/705) (70) 
DCP + AFP 90 mAU/mL, 45 ng/mL 84.4% (130/154) N (71) 
DCP + AFP 100 mAU/mL, 100 ng/mL 72.4% (55/76) N (72) 
DCP + AFP 100 mAU/mL, 300 ng/mL 63.2% (48/76) N (72) 
DCP + AFP 150 mAU/mL, 20 ng/mL 86% (-/-) † 63% (-/-) † (42) 
DCP + AFP 619 mAU/mL, 27 ng/mL 74% (-/-) † 87% (-/-) † (42) 
DCP + AFP 0.8 ng/mL, 45 ng/mL 88.3% (136/154) N (71) 
DCP + AFP 20.24 ng/mL, 15 ng/mL 94.0% (47/50) 80.5% (33/41) (73) 
DCP + AFP 0.1µg/mL, 20 ng/mL 92.9% (65/70) 53.3% (24/45) (74) 
DCP + AFP 0.1 mg/mL, 400 ng/mL 85.7% (60/70) 82.2% (37/45) (74) 
DCP + AFP 40 mAU/ml, 20 ng/ml 78.3% (47/60) 56.7% (17/30) (54) 
DCP + AFP 8 mAU/mL, 20 ng/mL 66.7% (18/27) N (63) 
DCP + AFP 16 mAU/mL, 20 ng/mL 82.9% (29/35) 84.0% (158/188) (64) 
DCP + AFP 40 mAU/mL, 20 ng/mL 59.4% (-/-) † 58.9% (53/90) (55) 
DCP + AFP 150 mAU/mL, 20 ng/mL 78% (-/-) † 62% (-/-) † (42) 
DCP + AFP 598 mAU/mL, 11 ng/mL 70% (-/-) † 80% (-/-) † (42) 
DCP + AFP 16 mAU/mL, 20 ng/mL 61.5% (8/13) 84.0% (158/188) (64) 
DCP + AFP 40 mAU/mL, 20 ng/mL 83.7% (36/43) N (65) 
DCP + AFP 40 mAU/mL, 200 ng/mL 47.5% (29/61) 98.5% (132/134) (43) 
* In all studies indicated, patients with chronic hepatitis and/or liver cirrhosis were designated as the 
comparative non-HCC patient group. Sensitivity = True positive (TP) / (TP + Falsenegative (FN)), Specificity 
= True negative (TN) / (TN + False positive (FP)). † The patient distribution was not noted. N, Not noted or 
not investigated. 
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HCC are infected with hepatitis C virus (HCV), and approximately 15-20% of patients are 
infected with HBV (81), these figures are similar to those reported from the United States 
and Europe (82, 83). According to HCC Guidelines in Japan, ultrasonography and the 
simultaneous measurement of DCP and AFP are recommended to be performed every 3-4 
months for the highest-risk group (HBV- or HCV-related liver cirrhosis patients) and every 
6-month for the high-risk group (patients with HBV- or HCV-related chronic liver disease 
or liver cirrhosis due to other causes) (17, 19). Currently, in Japan, DCP and AFP are 
widely and routinely used as serum biomarkers for HCC early diagnosis, which benefit 
more than 60% of patients that could be detected in the early stage (52), and these tests 
have been covered by Japan' national health insurance. 
The diagnostic effectiveness of DCP in HBV-related HCC is required for the 
diagnostic marker used in China. The present study analyzed the clinical utility of 
simultaneous measurement of DCP and AFP in differentiating Chinese HCC patients 
(74.18% with HBV infection) from those patients with non-HCC and normal subjects. 
Among 1,153 cases in this study, 550 cases were patients with HCC; for the control groups, 
patients with non-HCC disease of the liver, bile ducts, or pancreas underwent surgery – 164 
cases in Malignant disease group and 181 cases in Benign disease group – were enrolled; 
besides, we also collected the blood samples and information from 85 patients in Chronic 
liver disease group, as well as 173 volunteers of healthy subject in Normal group as 
controls. Results showed that DCP was an useful serum biomarker in diagnosis for Chinese 
patients with HCC predominantly caused by HBV infection; for the cases enrolled in our 
study, DCP with a cut-off value of 86 mAU/mL had a high specificity, PPV, and Youden 
index than a cut-off value of 40 mAU/mL; the combined testing of DCP with a cut-off 
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value of 86 mAU/ml and AFP with a cut-off value of 21 ng/mL resulted in a greater 
sensitivity and higher Youden index than DCP or AFP alone in differentiating patients with 
HCC from the other four groups of subjects, which suggest that DCP could be a good 
candidate as a compliment to AFP in HCC diagnosis for Chinese patients predominantly 
caused by HBV infection. 
Some studies have reported that the serum levels of DCP increase in relation to the 
size of HCC (76, 84, 85), it was also shown in our study that for patients with HCC, the 
median DCP level increased with a larger tumor, and the sensitivity of DCP with a cut-off 
value of 86 mAU/ml increased from 53.66% to 86.00% along the enlargement of tumor 
size. For the relation between AFP levels and tumor size, although the cases with tumor size 
of ≤ 2.0 cm and cases of 2-3 cm showed a relative high AFP level due to the classification 
difference, but in general, for cases ≤ 10.0 cm, the median AFP level was within 400 ng/mL 
(216.10 ng/mL for 41 cases ≤ 2.0 cm, 297.63 ng/mL for 99 cases ≤ 3.0 cm, 206.40 ng/mL 
for 205 cases ≤ 5.0 cm). In our study, the higher level of AFP was mainly in larger tumor 
size, showed a median AFP level of 2,265.00 ng/mL for patients with a tumor > 10.0 cm, 
which was significantly higher than that in patients with a smaller tumor, it was consistent 
with previous research findings. Likewise, although the sensitivity of AFP showed a 
relative high value for cases of ≤ 2.0 cm and cases of 2-3 cm due to the classification 
difference, in general, the sensitivity of AFP with a cut-off value of 21 ng/mL was 67.80% 
for 205 cases ≤ 5.0 cm. In the present study, the combination of DCP with a cut-off value 
of 86 mAU/mL and AFP with a cut-off value of 21 ng/mL resulted in a sensitivity of 
approximately 90%, which was significantly higher than that for DCP or AFP alone. The 
same was true even for a tumor smaller than 2.0 cm. These results suggest that the 
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simultaneous measurement of AFP and DCP may facilitate the diagnosis of patients with a 
broad range of HCC.  
Besides the investigation on using DCP as a useful serum biomarker for HCC 
diagnosis, several studies have also showed the association between elevated level of serum 
DCP and a poor clinical outcome in HCC patients (69, 86-88). Results indicated that DCP 
was clinically effective as a serum biomarker for the prediction of patient prognosis (75, 
89-91). Shirabe et al. examined 218 HCC patients who underwent surgical resection for 
HCC and concluded that serum DCP level is a predictor of microvascular invasion (92); 
Shimada et al. examined reported that serum DCP level is associated with vascular invasion 
and HCC recurrence (93); Inagaki et al. reported that patients with a high serum DCP level 
(5-year survival rate of 25.95%) had a significantly worse prognosis than those with a low 
serum DCP level (5-year survival rate: 25.95% vs. 55.56%; P = 0.002) (94). Some other 
studies have also showed serum DCP levels correlated significantly with 
clinicopathological factors of TNM stage, tumor size, and tumor differentiation (47, 89, 
95). 
However, all the studies mentioned above were focusing on HCV-related HCC, 
there was few report about the relationship between serum DCP level and HBV-related 
HCC. Focusing on the prognostic value of DCP in Chinese patients with HBV-related HCC, 
the present study indicated that high serum DCP levels were significantly frequent in 
patients who were with larger tumor size, poorly differentiated tumor, presence of 
microvascular invasion, more advanced TNM stage, or presence of tumor recurrence. In 
our study, the 3-year survival for HCC patients with high serum DCP levels was 
significantly poorer than that those with low serum DCP levels (3-year survival rate: 54.53% 
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vs. 81.82%, P = 0.007). These results suggest that DCP can be used for evaluation of 
HBV-related HCC prognosis and support the decision of treatment strategy. 
There are some limitations in the present study. First, this study did involve a 
relatively large number of patients with HCC, but all of those patients underwent curative 
surgery. Hence, patients with HCC in a more advanced stage were not included in this 
study. Besides, very few cases in Malignant disease group and Benign disease group 
showed a high DCP level, although they have been confirmed as non-HCC cases based on 
laboratory examination, imaging findings, pathologic findings from resected specimen, and 
none of cases received warfarin or other vitamin K inhibitor during the week prior to blood 
samples collection, but the mechanism research on the relation between high level of DCP 
and disease status for these cases need to be further investigated. Second, although the 
relation between DCP expression and the prognosis for Chinese patients with HCC has also 
been confirmed by the present study, the date were from a small subjects group that 
involving 112 HBV-related HCC cases, the date of prognosis for other patients with HCC 
that enrolled in the present study is now in collection. Third, besides the clinical 
effectiveness of serum DCP in HCC diagnosis and prognosis, DCP has also been routinely 
used for the screening and post-treatment monitoring for HCC patients in some countries, 
such as Japan. For the clinical effectiveness of serum biomarker DCP as a screening tool 
and post-treatment monitoring tool for Chinese patients with HCC, more large-scale 
national prospective studies should be conducted to complement to this study and provide 
sufficient evidence. 
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5. Conclusion 
 
Evidences have showed that early diagnosis of HCC is essential when curative 
interventions can be implemented to improve patients’ prognosis and long-term survival. 
Due to the fact that there is greatly large number of HBV carrier in China and those people 
are expected to be affected chronic viral hepatitis, liver cirrhosis and HCC, therefore, the 
early diagnosis for Chinese HCC patients predominantly caused by HBV infection has 
important implications not only for China, but also for the worldwide to reduce the burden 
of disease. 
In China, AFP as a serum biomarker has been widely used in clinical practice, but 
its disadvantage of low sensitivity, low specificity, and limited accuracy in detecting small 
HCC diminish its clinical utility in HCC early diagnosis. Thus, other reliable serum 
biomarkers need to be identified to complement AFP in order to improve clinical outcomes 
for patients with HCC in China.  
Worldwide, although DCP is known to be useful serum biomarker for the 
diagnosis of HCC and could also serve as a preoperative indicator in assessing HCC 
progression, the clinical usefulness of DCP in Chinese patients with HCC predominantly 
caused by HBV infection has yet been fully confirmed. 
This large-scale, multi-center case-controlled study involving 1,153 Chinese cases 
indicated that the simultaneous measurement of DCP and AFP could achieve a better 
sensitivity in diagnosing Chinese patients with HCC predominantly caused by HBV 
infection. The sensitivity of combined testing of two markers was significantly higher than 
that of either marker alone, the same was true even for a tumor smaller than 2.0 cm. To 
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improve the diagnostic ability of serum biomarkers for HCC in China, the combined usage 
of DCP and AFP is suggested by this study.  
Furthermore, the relation between DCP expression and the prognosis for Chinese 
patients with HCC has also been confirmed by the present study, which suggested that 
serum DCP could serve as a preoperative indicator in assessing progression for Chinese 
patients with HCC.  
With the impetus of this Japan-China joint research project, currently, DCP has 
been used in actual clinical practice in some hospitals of China since DCP approved to be 
used in China in 2014. With the increased application in clinical practice, the test of DCP is 
expected to be routinely used in China, with the goal of not only improving clinical 
outcomes for Chinese patients with HCC, but also reducing the disease burden globally due 
to the fact that China alone accounts for 50% of HCC cases worldwide. 
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